Antibody-drug conjugates (ADCs) are revolutionising oncology treatments because of their ability to precisely target tumours with toxic payloads that kill cancer cells without causing significant harm to normal tissues.
ADC developers have dramatically improved upon the original technology developed more than 20 years ago by further developing the components of the drugs, including the monoclonal antibodies, the cytotoxic payloads and the linkers connecting the payloads to the antibodies.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.